HCPCS code S0157 – Becaplermin gel (Regranex)

Key takeaways

HCPCS code S0157 bills becaplermin gel 0.01% (Regranex) in units of 0.5 g, so one 15 g tube equals 30 units.

The gel is FDA-approved for lower-extremity diabetic neuropathic ulcers that reach subcutaneous tissue or deeper and have an adequate blood supply.

S0157 carries CMS coverage code I, so Medicare does not pay it. NCD 270.3 lists becaplermin as nationally non-covered under Part B.

Medicaid and commercial plans that accept S0157 usually want prior authorization, a diabetic foot ulcer diagnosis and proof of ongoing wound care.

An L97 code with a sixth character of 2 or higher shows the ulcer depth the label requires. A 1 or a 9 invites a denial.

What is HCPCS code S0157?

HCPCS code S0157 is the Level II code for becaplermin gel 0.01%, 0.5 gm, sold under the brand name Regranex. Becaplermin is a recombinant human platelet-derived growth factor. The patient or a caregiver applies it to a diabetic foot ulcer once a day.

The code sits in the S0012–S0197 block of non-Medicare drug codes. It took effect on January 1, 2001, and it is still active in the October 2026 CMS HCPCS file. Its coverage code is I, which means Medicare does not pay it. Medicaid programs and commercial plans are the payers that use it.

S0157 bills the drug only. Debridement, wound assessment and dressing changes are reported with their own codes, such as CPT 11042 for subcutaneous debridement.

What the FDA label approves becaplermin for

The Regranex label approves the gel for lower-extremity diabetic neuropathic ulcers that extend into subcutaneous tissue or beyond and have an adequate blood supply. It is an adjunct to good ulcer care, which the label defines as initial sharp debridement, pressure relief and infection control.

Payers read the label’s limits as exclusions, so they shape which claims get paid:

• Pressure and venous stasis ulcers: efficacy has not been established for either wound type.
• Shallow or ischemic diabetic ulcers: the gel was not evaluated on ulcers above subcutaneous tissue (IAET stage I or II) or on ischemic ulcers.
• Wounds that close by primary intention: the label says the gel is not intended for them.
• Neoplasm at the site: a known neoplasm at the application site is a contraindication.
• Patients under 16: safety and effectiveness have not been established in that age group.

The FDA removed the boxed warning on cancer mortality in November 2018. The label still asks prescribers to weigh benefits and risks in patients with a known malignancy.

The product also changed hands. The May 2026 label records a new BLA holder, and the current tube carries NDC 85822-734-15 from LRM Therapeutics. Older Smith & Nephew stock carries NDC 50484-810-15, so check which tube was dispensed before you enter the NDC.

How to calculate S0157 units

One unit of S0157 equals 0.5 g of becaplermin gel. Divide the grams dispensed by 0.5 to get the units, so a full 15 g tube is billed as 30 units.

The label sizes the daily dose from the ulcer. Measure its greatest length and greatest width, then apply the formula for the unit of measure you used.

Take a 4 cm by 2 cm ulcer as an example. The formula gives 2 cm of gel a day, which weighs 0.5 g, or one unit. Thirty days at that size use the whole 15 g tube, which is 30 units. The chart below walks through the same numbers.

The label tells the clinician to recalculate the dose every week or two as the ulcer shrinks, so later tubes last longer. Treatment should be reassessed if the ulcer has not shrunk by about 30% after 10 weeks, or healed by 20 weeks. Confirm with each payer whether it wants units per tube dispensed before the first claim.

ICD-10-CM codes to pair with S0157

An S0157 claim needs two diagnosis codes. The first is the diabetes code with foot ulcer, such as E11.621. The second is an L97 code that records the ulcer’s site and depth, because E11.621 tells coders to add an L97.4- or L97.5- code.

The sixth character of the L97 code records depth, and many S0157 claims fail on it. A 1 means the breakdown is limited to skin, which falls short of the label. A 2 (fat layer exposed) or deeper matches it, while a 9 leaves the depth unproven.

Pressure ulcer codes from category L89 do not support S0157, and neither do venous stasis ulcer diagnoses. The label excludes both wound types, and payer policies follow it.

Modifiers used with S0157

S0157 has no modifier of its own. The ones below come up when a payer policy asks for an attestation, or when the gel falls outside a plan’s benefit.

Add a modifier only when the payer asks for it. An unrequested KX or GY can send a clean claim to manual review.

Payer coverage for HCPCS code S0157

Coverage for HCPCS code S0157 depends on the payer type, and Medicare does not pay it at all. Check the patient’s plan before the gel is dispensed, as part of your wider revenue cycle management.

Why Medicare does not pay S0157

Medicare’s answer sits in NCD 270.3. Since April 27, 2006, becaplermin has been nationally non-covered under Part B because the patient usually applies it. Part B pays for drugs that are not usually self-administered, and a gel used at home every day does not qualify.

The HCPCS file reflects that with coverage code I. A Medicare contractor will not pay an S0157 line, whatever the documentation shows.

What Medicare uses instead

Medicare beneficiaries get becaplermin through their Part D drug plan. The prescriber sends a prescription, the pharmacy dispenses the tube and bills the plan by NDC, and no HCPCS code is involved. The practice’s part is any prior authorization the plan requires.

The practice still bills its own wound care to Part B. Selective debridement, for example, is reported with CPT 97597. The gel never appears on that claim.

What commercial plans ask for

The two commercial policies we checked both sit in pharmacy programs and both require prior authorization:

• UnitedHealthcare (program 2026 P 1087-13): approves a lower-extremity diabetic neuropathic ulcer treated alongside wound care such as debridement, infection control or pressure relief. Authorization lasts 6 months.
• UnitedHealthcare automation: a prescription processes automatically when the member has a diabetes medication claim in the previous 180 days.
• Cigna (IP0495, effective October 1, 2026): requires a patient aged 16 or over, an IAET stage III or IV ulcer and standard ulcer care. Approval lasts 5 months.
• Cigna exclusions: pressure ulcers, venous stasis ulcers and ulcer prevention are not medically necessary uses.

Medicaid criteria vary by state, so read the state manual or the managed care plan’s pharmacy policy before the first fill. Solid medical billing compliance starts with that check.

Common denial reasons for S0157 claims

Most S0157 denials trace back to a decision made before the claim was built. Each rejection comes back with a reason code, and our guide to medical billing denial codes explains how to fix the common ones.

• Billed to Medicare: coverage code I means no payment. Route Medicare patients to their Part D plan through a prescription.
• No prior authorization, or an expired one: UnitedHealthcare approvals last 6 months and Cigna approvals 5. Record the end date and renew before it passes.
• Depth not supported: an L97 code ending in 1 or 9, or notes without depth, fails the subcutaneous threshold. Code and chart the measured depth.
• Excluded wound type: pressure ulcers and venous stasis ulcers fall outside the label. Confirm the ulcer is diabetic and neuropathic before billing.
• Unit mismatch: units must equal the grams dispensed divided by 0.5. A 15 g tube is 30 units.
• Wrong NDC: where the payer wants an NDC on the drug line, it must match the tube dispensed. Current stock carries 85822-734-15.
• No evidence of standard ulcer care: payers expect debridement, offloading and infection control alongside the gel. Chart each one.
• Renewal without progress: the label calls for reassessment when the ulcer has not shrunk about 30% by week 10. A renewal request without measurements invites a denial.

Documentation checklist for S0157 claims

A complete record is what turns an S0157 line into a clean claim. Check each item before the claim goes out.

• Diabetes type and foot ulcer diagnosis, coded E10.621, E11.621 or E13.621 with an L97 site-and-depth code
• Dated ulcer measurements (length, width and depth), showing the ulcer reaches subcutaneous tissue or beyond
• The neuropathic origin of the ulcer, with the neuropathy diagnosis where it is coded
• The vascular assessment the prescriber used to judge the blood supply adequate
• Standard ulcer care in the notes: sharp debridement, pressure relief and infection control
• The prescription, with the calculated daily length of gel and the number of tubes dispensed
• Units equal to grams dispensed divided by 0.5, plus the NDC of the tube dispensed
• The prior authorization number and its end date
• Follow-up measurements every week or two, with the 10-week and 20-week reassessments
• A review of any known malignancy, since the label asks prescribers to weigh benefits and risks

Wound care teams that work this list before each claim spend less time appealing.

How Pabau keeps wound care drug claims together

A becaplermin claim draws on three records: the wound measurements, the prior authorization and the claim. When they sit in separate systems, the biller chases the depth from a scanned note and the authorization lapses unnoticed.

Pabau, the practice management platform we build, keeps clinical notes and billing on one patient record. The prior authorization code, dates and sessions are tracked on the case, with a warning when one is missing. US prescriptions go out through DoseSpot e-prescribing.

Pabau’s claims management software sends CMS-1500 claims through the Claim.MD clearinghouse. Eligibility checks and electronic remittances come back to the same record, so your team sees a denial the day it posts.

Keep wound care records and claims in one place

Pabau tracks prior authorizations on the patient case and sends claims through the Claim.MD clearinghouse. See how it supports drug and wound care billing.

Book a demo

Conclusion

S0157 looks like a simple drug code, yet Medicare excludes the gel it bills and most other payers restrict it. Whether a payer covers it comes down to the wound record, more than the claim form. Depth, neuropathic origin and blood supply decide the first approval, and the measurements at each visit decide the renewal.

A practice that charts those facts at every visit rarely has to argue for the gel later. Book a demo to see how Pabau keeps wound records, authorizations and claims on one patient record.

Continue your research

Need help managing claim denials systematically? Denial management in healthcare covers the upstream controls that prevent the most common payer rejections.

Frequently asked questions